NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of California on behalf of all persons or entities who purchased or otherwise acquired MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) securities between March 14, 2016 and May 18, 2018 (the “Class Period”). Investors have until August 3, 2018 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The complaint alleges that Defendants made false and/or misleading statements, as well as failed to disclose: (1) that the Company’s internal controls over financial reporting were materially weak and deficient; (2) that the Company had incorrectly calculated and reported beneficial ownership of MabVax shares, and permitted improper influence or control over MabVax, and/or the Company’s officers and directors by certain shareholders; and, (3) that, as a result of the foregoing, the Company’s financial statements and Defendants’ statements about MabVax’s business, operations, and prospects, were materially false and misleading at all relevant times.
If you purchased or otherwise acquired MabVax securities during the Class Period or continue to hold shares purchased during the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning the MabVax Therapeutics Holdings, Inc. lawsuit, please go to https://bespc.com/mabvax/. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.